Metabolomics: Novel Pathophysiological Insights in Pregnancies Affected by Type 1 Diabetes  

Professor of Chemical Pathology and Diabetes in Pregnancy at Leicester Diabetes Centre

LinkedIn: https://www.linkedin.com/in/claire-meek-39b97a3b/

X (Twitter): https://twitter.com/ClaireMeek5

Website: https://www.mrl.ims.cam.ac.uk/research/principal-investigators/claire-meek/

Claire Meek is Professor of Chemical Pathology and Diabetes in Pregnancy at Leicester Diabetes Centre. She runs the diabetes in pregnancy service at University Hospitals Leicester, which includes a large, ethnically and socioeconomically diverse cohort of women with early-onset type 2 diabetes (EoT2D). She runs observational and interventional studies to improve clinical outcomes for women with diabetes in pregnancy.

Prof. Meek started her research career at the University of Cambridge, studying nutritional interventions to improve glycemia and weight loss in people with type 2 diabetes. Postdoctorally, she contributed to the CONCEPTT trial, assessing real time continuous glucose monitoring in type 1 diabetes in pregnancy, translated into clinical care internationally. In 2018, she received a Diabetes UK intermediate clinical fellowship to run a RCT of a dietary intervention in gestational diabetes (DiGest trial; recently finished). She also received a Future Leaders’ Award from the European Foundation for the Study of Diabetes (2019) in association with the Novo Nordisk Foundation, assessing progression to EoT2D after gestational diabetes.

Prof. Meek has received several other national and international awards including from the American Diabetes Association, the European Diabetes in Pregnancy Study Group, the Association of Physicians (UK), and the British Medical Foundation.

Field Metabolomics Scientist at Metabolon

Dr. Busetti is one of Metabolon’s most experienced Field Metabolomics Scientists and supports client projects across Europe and Asia. Alessandro obtained his bachelor's degree in biology and his master’s degree in molecular biology at the University of Rome, La Sapienza. He obtained his Ph.D. in pharmaceutical microbiology at The Queen’s University, Belfast (QUB).

Dr. Busetti spent 10 years conducting research in academia, both as a Research Fellow at QUB and as a Research Associate at the University of Glasgow. His research focused on the discovery of marine-derived bioactives for biomedical applications and understanding the role of microbiomes in regulating host health.

In 2016, he transitioned into the industry and joined 4D Pharma PLC, where he worked as the Senior Team Leader of the “Discovery-Micro” Department. There, he defined and implemented screening strategies to identify candidate LBP strains for a number of disease areas ranging from autoimmune diseases, solid tumors, neurodegenerative diseases, and more.

Dr. Busetti is a true scientific chameleon with a broad knowledge of many research areas of focus, but his main passion remains host-microbe interactions, microbiome studies, and “socio-microbiology.” He is based in Verona, Italy, where he lives with his wife and daughter.